title: Antibodies to B7.1 define the GFCC'C" face of the N-terminal domain as critical for co-stimulatory interactions.
abstract: Antagonists of the B7 family of co-stimulatory molecules have the potential for altering immune responses therapeutically. To better define the requirements for such inhibitors, we have mapped the binding of an entire panel of blocking antibodies specific for human B7.1. By mutagenesis, each of the residues critical for blocking antibody binding appeared to fall entirely within the N-terminal V-set domain of B7.1. Thus, although antibody-antigen interacting surfaces can be quite large, these results indicate that a relatively small portion of the GFCC'C" face of this domain is crucial for further antagonist development.
authors.affiliation: Wyeth Research, 200 Cambridge Park Drive, MA 02140, USA.
authors.forename: Suyue
authors.initials: S
authors.lastname: Wang
authors.forename: Geertruida M
authors.initials: GM
authors.lastname: Veldman
authors.forename: Mark
authors.initials: M
authors.lastname: Stahl
authors.forename: Yuzhe
authors.initials: Y
authors.lastname: Xing
authors.forename: James F
authors.initials: JF
authors.lastname: Tobin
authors.forename: David V
authors.initials: DV
authors.lastname: Erbe
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D019138:Antibodies, Blocking / Q000235:genetics / Q000276:immunology; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology*; D019556:COS Cells; D018604:Epitope Mapping; D018985:Epitopes, B-Lymphocyte; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000276:immunology; D051379:Mice; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D019138:Antibodies, Blocking; D018122:B7-1 Antigen; D018985:Epitopes, B-Lymphocyte; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins